<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359551</url>
  </required_header>
  <id_info>
    <org_study_id>273CH001 (NSR-CHM-OS1)</org_study_id>
    <nct_id>NCT03359551</nct_id>
  </id_info>
  <brief_title>Natural History of the Progression of Choroideremia Study</brief_title>
  <acronym>NIGHT</acronym>
  <official_title>Natural History of the Progression of Choroideremia Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NightstaRx Ltd, a Biogen Company</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this natural history study is to gain a better understanding of the&#xD;
      progression of choroideremia (CHM) and add to the knowledge base for this rare disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial&#xD;
      was transferred to Biogen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2015</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best-Corrected Visual Acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (EDTRS)</measure>
    <time_frame>Up to Month 20</time_frame>
    <description>BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If &lt;20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Reading Performance using International Reading Speed Texts (IReST)</measure>
    <time_frame>Baseline up to Month 12</time_frame>
    <description>Reading performance will be evaluated prior to pupil dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Color Vision</measure>
    <time_frame>Baseline up to Month 12</time_frame>
    <description>Colour vision will be tested prior to pupil dilation. Each eye will be tested separately and in the same order.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Visual Fields</measure>
    <time_frame>Baseline up to Month 12</time_frame>
    <description>The progression of defects in visual fields will be assessed in both eyes using perimetry equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Contrast Sensitivity</measure>
    <time_frame>Baseline up to Month 12</time_frame>
    <description>Contrast sensitivity will be measured for both eyes, prior to pupil dilation, using a Pelli Robson chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Retinal Thinning Using Spectral Domain Optical Coherence Tomography (SD-OCT)</measure>
    <time_frame>Baseline up to Month 20</time_frame>
    <description>SD-OCT measurements will be performed after dilation of the participant's pupil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Area of Viable Retinal Tissue Using Fundus Autofluorescence</measure>
    <time_frame>Baseline up to Month 20</time_frame>
    <description>Fundus Autofluorescence will be performed after dilation of the participant's pupil to assess changes in the area of viable retinal tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Retinal Sensitivity Using Microperimetry</measure>
    <time_frame>Baseline up to Month 20</time_frame>
    <description>Macular analyser integrity assessment (MAIA) microperimetry will be conducted for both eyes to assess changes in retinal sensitivity within the macula.</description>
  </secondary_outcome>
  <enrollment type="Actual">319</enrollment>
  <condition>Choroideremia</condition>
  <eligibility>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Are willing and able to provide informed consent for participation in the study.&#xD;
&#xD;
          -  Have a clinical phenotype and confirmed genetic diagnosis of CHM.&#xD;
&#xD;
          -  Have active disease clinically visible within the macular region.&#xD;
&#xD;
          -  Are willing and able to undergo ophthalmic examinations once every 4 months for up to&#xD;
             20 months.&#xD;
&#xD;
          -  Have a BCVA better than or equal to 6/60 (20/200; decimal 0.1; LogMAR 1.0; 34-38 ETDRS&#xD;
             letters) in at least one eye.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of amblyopia in the eligible eye.&#xD;
&#xD;
          -  Have any other significant ocular or non-ocular disease/disorder in the eligible eye&#xD;
             which, in the opinion of the investigator, may put the subject at risk because of&#xD;
             participation in the study, influence the results of the study or influence the&#xD;
             subject's ability to participate in the study.&#xD;
&#xD;
          -  Have participated in an interventional research study in the past 6 months.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04552-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montréal</city>
        <zip>H3A 0E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <zip>74103</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hariri AH, Velaga SB, Girach A, Ip MS, Le PV, Lam BL, Fischer MD, Sankila EM, Pennesi ME, Holz FG, MacLaren RE, Birch DG, Hoyng CB, MacDonald IM, Black GC, Tsang SH, Bressler NM, Larsen M, Gorin MB, Webster AR, Sadda SR; Natural History of the Progression of Choroideremia (NIGHT) Study Group. Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved Retinal Pigment Epithelium Area in Eyes With Choroideremia. Am J Ophthalmol. 2017 Jul;179:110-117. doi: 10.1016/j.ajo.2017.05.002. Epub 2017 May 10.</citation>
    <PMID>28499705</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>REP1</keyword>
  <keyword>Retina</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Retinal Dystrophy</keyword>
  <keyword>Natural History</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

